The purpose of this study is to treat advanced or recurrent endometrial cancer,
paclitaxel-containing regimen is the preferred chemotherapeutic regimen which is selected by
most physicians. Docetaxel may have similar efficacy and more favorable treatment related
toxicity profile as tested in epithelial ovarian cancer trials. Therefore, the investigators
aimed to evaluate the efficacy and safety of docetaxel plus cisplatin in patients with
advanced or recurrent endometrial cancer.